Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Griebel

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Current Pharmaceutical Design|June 6, 2015
Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and TachykininsGuy Griebel
Nature Reviews. Drug Discovery|May 19, 2012
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Guy Griebel, Florian Holsboer
Nature Reviews. Drug Discovery|August 31, 2013
50 years of hurdles and hope in anxiolytic drug discoveryGuy Griebel, Andrew Holmes
Pharmacology & Therapeutics|October 4, 2011
Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?Guy Griebel, Sandra Beeské
European Journal of Pharmacology|August 24, 2004
Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depressionDavid H Overstreet, Guy Griebel
Pharmacology, Biochemistry, and Behavior|September 27, 2005
Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line ratDavid H Overstreet, Guy Griebel
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 6, 2003
Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in miceCecile Ducottet, Guy Griebel, Catherine Belzung
Physiology & Behavior|June 13, 2015
Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSDJulie Philbert, Catherine Belzung, Guy Griebel
Biological Psychiatry|February 5, 2005
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodentsGuy Griebel, Jeanne Stemmelin, Bernard Scatton
Pharmacology, Biochemistry, and Behavior|April 15, 2014
Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysisCatherine Belzung, Marc Turiault, Guy Griebel
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Current Pharmaceutical Design|June 6, 2015
Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and TachykininsGuy Griebel
Nature Reviews. Drug Discovery|May 19, 2012
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Guy Griebel, Florian Holsboer
Nature Reviews. Drug Discovery|August 31, 2013
50 years of hurdles and hope in anxiolytic drug discoveryGuy Griebel, Andrew Holmes
Pharmacology & Therapeutics|October 4, 2011
Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?Guy Griebel, Sandra Beeské
European Journal of Pharmacology|August 24, 2004
Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depressionDavid H Overstreet, Guy Griebel
Pharmacology, Biochemistry, and Behavior|September 27, 2005
Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line ratDavid H Overstreet, Guy Griebel
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 6, 2003
Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in miceCecile Ducottet, Guy Griebel, Catherine Belzung
Physiology & Behavior|June 13, 2015
Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSDJulie Philbert, Catherine Belzung, Guy Griebel
Biological Psychiatry|February 5, 2005
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodentsGuy Griebel, Jeanne Stemmelin, Bernard Scatton
Pharmacology, Biochemistry, and Behavior|April 15, 2014
Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysisCatherine Belzung, Marc Turiault, Guy Griebel
Pageof 7